Induction of prostaglandin G/H synthase-2 in a canine model of spontaneous prostatic adenocarcinoma

Journal of the National Cancer Institute

Volumn 91, Issue 16, 1999, Pages 1398-1403

  Tremblay, Claudine ^c   Doré, Monique ^c   Bochsler, Philip N ^a   Sirois, Jean ^b  

^a UNIVERSITY OF TENNESSEE   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ISOENZYME; POLYCLONAL ANTIBODY; PROSTAGLANDIN SYNTHASE;

AGE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOG; ENZYME INDUCTION; ENZYME LOCALIZATION; FIBROBLAST; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROSTATE ADENOCARCINOMA; STROMA; VASCULAR ENDOTHELIUM;

EID: 0033581177     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.16.1398     Document Type: Article

References (53)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1999. CA Cancer J Clin 1999; 49:8-31.
2. Maini A, Archer C, Wang CY, Haas GP. Comparative pathology of benign prostatic hyperplasia and prostate cancer. In Vivo 1997;11: 293-9.
3. Waters DJ, Sakr WA, Hayden DW, Lang CM, McKinney L, Murphy GP, et al. Workgroup 4: spontaneous prostate carcinoma in dogs and nonhuman primates. Prostate 1998;36:64-7.
4. Bell FW, Klausner JS, Hayden DW, Feeney DA, Johnston SD. Clinical and pathologic features of prostatic adenocarcinoma in sexually intact and castrated dogs: 31 cases (1970-1987). J Am Vet Med Assoc 1991;199: 1623-30.
5. Waters DJ, Bostwick DG. Prostatic intraepithelial neoplasia occurs spontaneously in the canine prostate. J Urol 1997;157:713-6.
6. Waters DJ, Hayden DW, Bell FW, Klausner JS, Qian J, Bostwick DG. Prostatic intraepithelial neoplasia in dogs with spontaneous prostate cancer. Prostate 1997;30:92-7.
7. Davidson D, Bostwick DG, Qian J, Wollan P, Oesterling JE, Rudders RA, et al. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J Urol 1995;154:1295-9.
8. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992;52:5575-89.
9. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6.
10. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part 1). J Natl Cancer Inst 1998; 90:1529-36.
11. DeWitt DL, Meade EA, Smith WL. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. Am J Med 1993;95(2A):40S-44S.
12. Funk CD. Molecular biology in the eicosanoids field. Prog Nucleic Acids Res Mol Biol 1993;45:67-98.
13. DeWitt DL, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from complementary DNA sequence [published erratum appears in Proc Natl Acad Sci U S A 1988;85:5056]. Proc Natl Acad Sci U S A 1988;85:1412-6.
14. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991;88:2692-6.
15. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promotor-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-72.
16. Sirois J, Richards JS. Purification and characterization of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles. J Biol Chem 1992;267:6382-8.
17. Herschman HR. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev 1994;13:241-56.
18. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-73.
19. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995;378:406-9.
20. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995;83:483-92.
21. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83:473-82.
22. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995;55: 2556-9.
23. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995;55:3785-9.
24. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-4.
25. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998;58:2929-34.
26. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57:1276-80.
27. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc delta 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
28. Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998;19:723-9.
29. Tjandrawinata RR, Dahiya R, Hughes-Fulford M. Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer 1997;75:1111-8.
30. Liu XH, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998;58: 4245-9.
31. Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998;77: 511-5.
32. Hall WC, Nielsen SW, McEntee K. Tumours of the prostate and penis. In: Bulletin of The World Health Organization, International Histological Classification of Tumors of Domestic Animals. Vol. 53. Geneva (Switzerland); 1976. p. 247-56.
33. Catafalmo JL, Dodds WJ. Isolation of platelets from laboratory animals. In: Hawiger J, editor. Methods in enzymology. Vol 169. San Diego (CA): Academic Press; 1989. p. 27-34.
34. Sirois J. Induction of prostaglandin endoperoxide synthase-2 by human chorionic gonadotropin in bovine preovulatory follicles in vivo. Endocrinology 1994;135:841-8.
35. Sirois J, Dore M. The late induction of prostaglandin G/H synthase-2 in equine preovulatory follicles supports its role as a determinant of the ovulatory process. Endocrinology 1997; 138:4427-34.
36. Dore M, Hawkins HK, Entman ML, Smith CW. Production of a monoclonal antibody against canine GMP-140 (P-selectin) and studies of its vascular distribution in canine tissues. Vet Pathol 1993;30:213-22.
37. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72: 248-54.
38. Drago JR, Al-Mondhiry AB. The effect of prostaglandin modulators on prostate tumor growth and metastasis. Anticancer Res 1984;4: 391-4.
39. Rose DP, Connolly JM. Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate 1991;18:243-54.
40. Viljoen TC, van Aswegen CH, du Plessis DJ. Influence of acetylsalicylic acid and metabolites on DU-145 prostatic cancer cell proliferation. Oncology 1995;52:465-9.
41. Chaudry AA, Wahle KW, McClinton S, Moffat LE. Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. Int J Cancer 1994;57:176-80.
42. Faas FH, Dang AQ, Pollard M, Hong XM, Fan K, Luckert PH, et al. Increased phospholipid fatty acid remodeling in human and rat prostatic adenocarcinoma tissues. J Urology 1996; 156:243-8.
43. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90:455-60.
44. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-14.
45. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-5.
46. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989;299:1247-50.
47. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-46.
48. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells over-expressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
49. Tsuji M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997;94:3336-40.
50. Tsuji M, Kawano S, Tsuji S, Sawaoka H, Hori M, Dubois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
51. Young MR. Eicosanoids and the immunology of cancer. Cancer Metastasis Rev 1994;13: 337-48.
52. Rhim JS, Kung HF. Human prostate carcinogenesis. Crit Rev Oncog 1997;8:305-28.
53. Waters DJ, Patronek GJ, Bostwick DG, Glickman LT. Comparing the age at prostate cancer diagnosis in humans and dogs. J Natl Cancer Inst 1996;88:1686-7.